PSMA-Targeted Therapy Market Forecast: Dramatic Growth Expected by 2034 The PSMA-targeted therapy market is projected to witness significant expansion by 2034 owing to increasing prostate cancer diagnoses, enhanced treatment awareness, and promising clinical trials.

PSMA-Targeted Therapy Market Forecast: Dramatic Growth Expected by 2034 #None #Telix_Pharmaceuticals #Lantheus #PSMA_Therapy

SHINE's Acquisition of Lantheus SPECT Expands Nuclear Medicine Leadership SHINE Technologies has completed the acquisition of Lantheus' SPECT business and appointed Michael Rossi as CEO of SHINE SPECT USA, marking a significant expansion in nuclear medicine.

SHINE's Acquisition of Lantheus SPECT Expands Nuclear Medicine Leadership #USA #Shine #Lantheus #Janesville #SPECT

Investors of Lantheus Holdings Can Pursue Class Action Suit Against Securities Fraud Lantheus Holdings investors can lead a lucrative class action lawsuit due to alleged securities fraud. Join by November 10, 2025, for compensation.

Investors of Lantheus Holdings Can Pursue Class Action Suit Against Securities Fraud #USA #New_York #Rosen_Law_Firm #Lantheus #LNTH

Lantheus Holdings Faces Class Action Lawsuit Over Securities Violations Investors of Lantheus Holdings, Inc. are reminded of a class action lawsuit due to alleged securities law violations, impacting shareholders significantly.

Lantheus Holdings Faces Class Action Lawsuit Over Securities Violations #United_States #Class_Action #Securities_Law #Eastchester #Lantheus

Faruqi & Faruqi Investigates Lantheus Claims: Investors Encouraged to Act Faruqi & Faruqi, a leading securities law firm, is investigating potential claims against Lantheus. Investors who faced losses are urged to contact them.

Faruqi & Faruqi Investigates Lantheus Claims: Investors Encouraged to Act #United_States #New_York #securities_lawsuit #Faruqi_&_Faruqi #Lantheus

Pomerantz Law Firm Cautions Investors About Lantheus Holdings Class Action Lawsuit A class action lawsuit has been filed against Lantheus Holdings, Inc. Investors are urged to take action before the deadline on November 10, 2025.

Pomerantz Law Firm Cautions Investors About Lantheus Holdings Class Action Lawsuit #None #Pomerantz #Lantheus #LNTH

SHINE Technologies Expands Leadership in Nuclear Medicine with Lantheus Acquisition SHINE Technologies has announced its acquisition of Lantheus' SPECT division, enhancing its position in nuclear medicine and market presence significantly.

SHINE Technologies Expands Leadership in Nuclear Medicine with Lantheus Acquisition #United_States #Lantheus #SHINE_Technologies #Janesville #SPECT_division

CytoSite Bio Partners with Lantheus for Innovative PET Imaging Radiotracer Development CytoSite Bio has entered a collaboration agreement with Lantheus to develop a Granzyme B-targeted PET imaging radiotracer, enhancing immunotherapy assessment. This partnership aims to pioneer advancements in monitoring immune response in oncology.

CytoSite Bio Partners with Lantheus for Innovative PET Imaging Radiotracer Development #USA #Boston #Lantheus #CytoSite_Bio #Granzyme_B

Lantheus Expands Reach with Evergreen Theragnostics Acquisition, Enhancing Radiopharmaceutical Leadership Lantheus continues to strengthen its position in the radiopharmaceutical sector by acquiring Evergreen Theragnostics for $250 million, unlocking new growth avenues.

Lantheus Expands Reach with Evergreen Theragnostics Acquisition, Enhancing Radiopharmaceutical Leadership #USA #Bedford #Lantheus #Evergreen_Theragnostics #OCTEVY